Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 2Breast Neoplasms 2Anatomic Stage III Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Renal Insufficiency, Chronic 1Prostatic Neoplasms 1Pleuropulmonary blastoma 1Pain 1Neuroblastoma 1Melanoma 1Leukemia, Hairy Cell 1Ganglioneuroblastoma 1Carcinoma, Renal Cell 1Carcinoma, Medullary 1Carcinoma, Intraductal, Noninfiltrating 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Magnetic Resonance Spectroscopy 47enzalutamide 46apalutamide 36Specimen Handling 30Androgen Antagonists 30Abiraterone Acetate 29Radiosurgery 26Prednisone 25darolutamide 24Docetaxel 23Pluvicto 21abiraterone 19Radiotherapy 19Biopsy 17Leuprolide 15Surveys and Questionnaires 11Radiation 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11relugolix 10gallium 68 PSMA-11 10acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 10Standard of Care 10Nivolumab 10cabazitaxel 9Triptorelin Pamoate 9bicalutamide 8Carboplatin 8pembrolizumab 7olaparib 7niraparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × High-Energy Shock Waves × 90 days × Clear all
NCT05828082 2026-05-13

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡